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Cutaneous T cell lymphomas are characterized by an
accumulation of malignant clonal lymphocytes in the
skin and occasionally in the blood. We compared
gene transcription pro®les from cultured clonal
lymphocytes with autologous healthy blood lympho-
cytes by microarray hybridization. Cutaneous T cell
lymphoma derived cells transcribed high amounts of
an interferon inhibiting cytokine factor. The
presence of an interferon inhibiting cytokine factor
was con®rmed in 12 skin biopsies of mycosis
fungoides and SeÂzary syndrome derived blood
lymphocytes by reverse transcriptase±polymerase
chain reaction. The presence of interferon inhibiting
cytokine factor mRNA in SeÂzary syndrome derived
lymphocytes was associated with a lack of HLA class
II upregulation after stimulation with interferon-a
and interferon-g. This was not due to a loss of the
interferon signaling cascade as the presence of inter-
feron-signaling components was con®rmed by
reverse transcriptase±polymerase chain reaction on
the transcriptional level. The elevated constitutive
interferon inhibiting cytokine factor expression
observed in cutaneous T cell lymphoma derived cells
was insensitive to interferon-g stimulation, but was
enhanced in normal peripheral blood mononuclear
cells. We suggest that interferon inhibiting cytokine
factor contributes to the lack of HLA class II upregu-
lation in lymphoma cells. Interferon inhibiting cyto-
kine factor may participate in providing a
microenvironment at the tumor site insensitive to
interferon-g stimulation and thus prevents an ef®-
cient local immune response. Key words: immune
escape/microarray hybridization/SeÂzary syndrome. J Invest
Dermatol 116:874±879, 2001
C
utaneous T cell lymphomas (CTCL) comprise a
heterogeneous group of neoplasms characterized by
an accumulation of malignant T lymphocytes in skin
and occasionally, as in SeÂzary syndrome (SS), in skin
and blood.
Based on clinical, histologic, and immunologic features, we
suppose that the tumor cells in SS and probably also in mycosis
fungoides (MF) are well differentiated skin homing (Kamarashev et
al, 1998) T helper 2 lymphocytes (Sterry and Mielke, 1989; Vowels
et al, 1994; Asadullah et al, 1996; Dummer et al, 1996), often
lacking CD7 expression (Wood et al, 1993) with a low proliferation
rate, but an increased expression of anti-apoptotic proteins, such as
bcl-2 in early stages and enhanced proliferation in advanced stages
(Dummer et al, 1995; Dummer et al, 2000). Recently, it was
demonstrated that clonal T cells derived from SS fail to respond to
interferon (IFN) -a and IFN-g (Dummer et al, 1998, 2001) and to
interleukin-12 (Showe et al, 1999). As tumor-speci®c molecular
alteration might present targets for future therapeutic strategies
(Rook et al, 1999; Dummer et al, 2001), we aim to identify genes
preferentially expressed in the malignant T cells.
The microarray technique is a powerful tool to identify
transcriptional differences between benign and malignant cells for
large numbers of genes (Sikic, 1999; Lockhart and Winzeler, 2000).
We perform microarray hybridization on isolated CTCL-derived
cells and compared the resulting pro®le with autologous healthy
peripheral blood derived T helper cells, otherwise displaying
widespread similarities. The IFN-g inhibiting cytokine (IK) ®rst
described by Krief et al (1994) appeared overexpressed in CTCL-
derived cells. This factor IK was shown to inhibit IFN-g induced
expression of HLA class II antigen.
MATERIALS AND METHODS
Patients MF and SS was diagnosed using standard clinical criteria
(Burg et al, 1995) (erythroderma, lymphadenopathy), histologic
(subepidermal lymphoid in®ltrate showing strong epidermotropism and
expressing a T helper cell phenotype), and for SS hematologic criteria
(more than 1000 SS cells per ml), and an elevated CD4/CD8 ratio (van
Willemze et al, 1983; Heald et al, 1994). All patients were seronegative
for human T cell lymphocytic virus I antibodies by enzyme-linked
immunosorbent assay. Patients did not receive any systemic therapy in
the last 2 wk before blood was taken; however, topical steroids had to
be applied to control itching. The biopsy site was spared at least 5 d
before tumor sampling. For detailed patient information refer to
Table I.
Manuscript received October 27, 2000; revised January 2, 2001;
accepted for publication January 31, 2001.
Reprint requests to: Dr. Reinhard Dummer, UniversitaÈtsSpital ZuÈrich,
Dermatologische Klinik, Gloriastr. 31, CH-8091 ZuÈrich, Switzerland.
Email: dummer@derm.unizh.ch
Abbreviation: IK, interferon inhibiting cytokine factor.
0022-202X/01/$15.00 ´ Copyright # 2001 by The Society for Investigative Dermatology, Inc.
874
Puri®cation and culture of malignant clones and normal CD4+
cells All human material was obtained with the patient's informed
consent. CD4+ cells were separated by an immunomagnetic procedure
using paramagnetic polystyrene beads (Dynal, Lake Success, NY) and a
magnetic separation device (Dynal). An anti-human CD4-speci®c murine
IgM antibody (Dako, Glostrup, Denmark) was conjugated to Dynabeads
M-450 (Dynal) by overnight incubation at pH 9.5, washed twice in
phosphate-buffered saline containing 10% fetal bovine serum and
incubated under constant slow agitation with peripheral blood
mononuclear cells (PBMC) generated by Ficoll gradient enrichment
from the patient's blood at 4°C. Puri®ed CD4+ T cells were stimulated
by exposure to 10mg per ml PHA (Gibco, Grand Island, NY) and
harvested on day 3.
Lymphocytic cells from a diagnostic MF tumor sample were cultured
for 8 wk in RPMI 1640 medium (500 ml), supplemented with 100 ml
fetal bovine serum (» 20%), 10 ml fungizone/streptomycin, 10 ml
glutamine, 5 ml sodium pyruvate (all Gibco BRL), 100 ml human
epidermal growth factor (= 1 mg), 200 ml interleukin-2 (106 u per ml),
2 ml interleukin-4 (50,000 u per ml), 2 ml granulocyte-monocyte col-
ony-stimulating factor (80,000 u per ml), and 400 ml basic ®broblast
growth factor (250,000 u per ml) (all Becton Dickinson, San Jose, CA).
Clonality of the morphologically homogenous tumor cell population was
determined by PCR/denaturing gradient gel electrophoresis as described
previously and compared with original cryopreserved biopsy material
(Wood et al, 1994). Autologous peripheral CD4+ T cells were cultured
for 3 d under identical conditions in order to normalize for tissue culture
artifacts.
Microarray hybridization Four different pairs of samples have been
analyzed. Total mRNA (3 mg) obtained from CTCL patient's derived
clonal T cell cultures and autologous normal CD4+ PBMC, respectively,
was reverse transcribed using the cDNA Synthesis (CDC) Primer Mix
including (a-32P)deoxyadenosine triphosphate into radioactively labeled
cDNA (Atlas TM Pure Total Labeling System, Clontech, Palo Alto,
CA). The probes were then hybridized to separate Atlas Arrays (``Human
Cancer'' comprising 588 different tumor-related genes) following the
manufacturer's instructions (Atlas TM cDNA Expression Array,
Clontech) and expression pro®les visualized by phosphoimaging scans.
Flow cytometry Surface receptor status of PBMC and CTCL cells
was analyzed using anti-HLA-ABC monoclonal antibody (MoAb) W6.32
(Dako Diagnostics, Zug, Switzerland), anti-HLA-DR MoAb L243
(BD/Pharmingen, Heidelberg, Germany), anti-IFN-a receptor 1 MoAb
(kindly provided by Dr. Novick), anti-IFNAR2 MoAb (Transduction
Laboratories, Maechler AG, Basel, Switzerland), anti-IFN-g receptor
(anti-IFNGR) 1 MoAb A6-C5 (kindly provided by Dr Hemmi, Institute
for Molecular Biology, ZuÈrich), anti-IFNGR2 MoAb Hub159
(Genzyme Diagnostics, Kings Hill, U.K.). As isotype control mouse
IgG1, IgG2a antibodies, and hamster IgG antibodies (all BD/
Pharmingen) have been used, respectively. As secondary reagents
¯uorescence conjugated rabbit anti-mouse (RAM) polyclonal antibodies
(Dako), biotin-labeled goat anti-hamster polyclonal MoAb (CALTAG,
Burlingame, CA) and ¯uorescence conjugated streptavidin (Dako) have
been used.
Reverse transcriptase±polymerase chain reaction (RT±PCR) For
IK, mRNA detection total mRNA was extracted from CTCL cell
cultures, tissue samples and PBMC culture using RNAeasy Mini Kit
(Qiagen AG, Basel, Switzerland), following the manufacturer's
instructions (Table I). In addition, from two SS patients (PL and XB)
and normal donor blood, PBMC were isolated with Ficoll-Paque
(Amersham, Uppsala, Sweden), pelleted, and then resuspended in buffer
A (10 mM HEPES, 10 mM KCl, 1 mM ethylenediamine tetraacetic
acid, 1 mM ethyleneglycol-bis-(b-aminoethylether)-N,N,N¢,N¢-
tetraacetic acid) and lyzed by vortexing with the addition of 1/16 vol. of
10% nonidet P40. The supernatant was added to an equal volume of
buffer B (7 M urea, 1% sodium dodecyl sulfate, 0.35 M NaCl). After
one phenol/chloroform/ethanol extraction the RNA was dissolved in
RNAse-free water. From all isolated RNA samples mounts between 2
and 4 mg RNA were used to synthesize cDNA (M-MuLV Reverse
Transcriptase from New England Biolabs, Beverly, MA). PCR was
performed with the incubation buffer supplied with the Taq DNA
polymerase (Boehringer Mannheim, Mannheim, D), with PCR
digoxigenin labeling nucleotide mix (Boehringer Mannheim), and with
2.0 mM oligonucleotide primers. The cDNA probes were ®rst ampli®ed
with primers for b-actin to test the quality and quantity of the cDNA.
Only satisfactory cDNA was then subjected to PCR with primers for
Table I. Patient characteristicsa










ZK F 35 PBMC, healthy donor ND ± ND
MD M 63 Psoriasis vulgaris ± ND ND
MB F 42 Psoriasis vulgaris ± ND ND
BR F 36 Psoriasis vulgaris ± ND ND
MT M 45 Eczema ± ND ND
HT M 30 Eczema ± ND ND
AE M 61 Atopic dermatitis (+) ND ND
VM M 74 Parapsoriasis en grande plaques Ia ND + +
DM F 50 Mycosis fungoides IIb + ND ND
TR M 47 Mycosis fungoides IVa + ND +
RM F 47 Mycosis fungoides IVa + (NS) + +
SW M 65 Mycosis fungoides IVa + (NS) + +














SM F 62 SS 8.1 III + ND
CT F 53 SS 12.0 III + 50 80.0
ZA F 69 SS 6.3 III + 33
WR F 62 SS 16.1 III + 67
XB M 64 SS 15.1 III + 80 73.8
KH F 67 SS 6.0 IVa + 60
PL M 56 SS 12.0 IVa ND 74 81.3
aND, not determined; NS, not shown; EORTC, European Organization for Research and Treatment of Cancer.
bClonal dominance of T cell receptor Vb chain of all CD4+ cells
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IFNAR1 and 2, IFNGR1 and 2, JAK-1 and STAT-1, respectively.
Table II shows the primer sequences. Intron-spanning primers were
selected using the OLIGO Primer Analysis Software program version 4.0
(National Biosciences, Cascade, CO). Primer sequences were sent to
GenBank to exclude cross-binding to other published sequences
(Altschul et al, 1990). PCR was performed with Perkin Elmer 9600
GenAmp cyclers (Wellesley, MA). DNA-fragments were ampli®ed with
30 cycles and an annealing temperature of 55°C. An aliquot of PCR
product was electrophoresed on a 1.6% agarose gel and visualized by
ethidium bromide staining. In all PCR reactions positive controls from
various cell lines and water as negative control were included.
Real-time quantitative PCR A Hot-Start PCR was performed using
2ml ready-to-use mastermix (LightCycler ± Faststart DNA Master SYBR
Green I, Roche Molecular Biochemicals, Mannheim, Germany),
containing thermostable recombinant Taq polymerase, reaction buffer,
deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxy-
guanosine triphosphate, deoxyuridine triphosphate), 0.5 mM of each
oligonucleotide primers (Microsynth, Balgach, Switzerland), variable free
MgCl2 concentrations, 2 ml cDNA and water to a ®nal volume of 20 ml.
Ampli®cation occured as a three-step cycling procedure: denaturation
95°C, 15 s; annealing 66°C, 10 s; and elongation 72°C, 18 s for 40
cycles. External standards for the b-actin quantitation consisted of four
serial 1 : 10 dilutions (5.4 3 104 to 5.4 3 107 copies per reaction) of a
pCR2.1 b-actin plasmid. External standards were run concomitantly
with patients' samples under identical conditions. The ¯uorescence signal
was plotted against the cycle number for all samples and external
standards. The Fit Points method option was used in the course of
analyzing quantitation data, allowing the de®nition of a noise band and
subsequent background ¯uorescence subtraction, and resulting in the
display of only log-linear and plateau ampli®cation phases. A standard
curve was then generated for each run, plotting the crossing point
against the log-concentration of the standards. Normalization of
estimated IK amounts was achieved by calculating the ratios between IK
and b-actin, in order to compensate the variations in quantity and
quality of starting mRNA. Ten microliters of each ampli®cation product
were checked by electrophoresis on a 2% agarose gel stained with
ethidium bromide. The estimated size of the ampli®ed fragments
matched the calculated size. Product identity was in parallel checked by
melting curve analysis, which is another application in the LightCycler
analysis program.
RESULTS
Overexpression of IK mRNA in cutaneous lymphoma cells
detected in microarray hybridization Total RNA of patient's
skin derived CTCL cell cultures was isolated and subjected for
hybridization with 588 tumor-related genes on a microarray. An
overlay subtracts the hybridization signal obtained with CTCL
cells, from the signal obtained with autologous healthy PBMC
(SW, TR) or with allogenic CD4+ cells (VM, RM). A consistent
overexpression in all four microarray tested patient samples was
found for the IK mRNA. Figure 1 demonstrates the microarray
hybridization results for patient SW. Subsequent reverse
transcriptase±PCR analysis with extended patient numbers
revealed the presence of the IK mRNA in 11 skin biopsies,
blood samples or cell cultures of CTCL patients and the lymphoma
cell line Jurkat (Table I, Fig 1 insert). In contrast to that, RNA
isolated from healthy donor's PBMC showed no band (ZK). The
same was true for RNA isolated from CD7+ cells of the SS patient
KH (Fig 1 insert; KH1).
Unresponsiveness of patient's PBMC to IFN
stimulation As IK was found to be overexpressed in CTCL
cells we asked, whether IFN are still effective on CTCL cells and if
they can stimulate the HLA class II expression in these cells. A clear
upregulation of HLA class II expression with either IFN-a or IFN-
g was only seen in gated lymphocytes from healthy controls but not
in gated lymphocytes derived from two SS patients with high
clonality (XB, PL), although a basic level of HLA class II protein
expression was detected (Fig 2). Jurkat cells did not express HLA
class II at all.
Differential expression of IFNR chains on patients' PBMC
and healthy donor PBMC The patients XB and PL were tested
for expression of IFNR chains and associated proteins by
Table II. Primer sequencesa
Gene 5¢-primer (5¢-3¢) 3¢-primer (5¢-3¢) amplicon size (bp)
IFNAR1 TTG CTC TCC CGT TTG TCA TTT A GAC CTC AGG CTC CCA GTG TAA C 395
IFNAR2 CCA CCT CTA CAG AAT CCC AGT T GGA GAA CAC TTG CAG ACG ATA A 591
IFNGR1 TTG GAT TCC AGT TGT TGC TGC TT TGT CCA GGA AAA TCA GAC TTC AA 775
IFNGR2 CCT CCA CTG AGC TTC AGC AAG TC CAA AAG GGA ATA CTG GTC TCT GG 394
STAT-1 CAA GGT GGC AGG ATG TCT CAG TG TGG TCT CGT GTT CTC TGT TCT GC 565
JAK-1 GGA CCC CAC ACA TTT TGA GAA GC TGC AGA GTG ACT CCA AAA GAC CA 645
IK GCA GCT GGG AGA TTT CTT TG GGG CAA AGC TTC TTT GTT GT 148
b-actin CGA CAA CGG CTC CGG CAT GTG C CGT CAC CGG AGT CCA TCA CGA TGC 419
aAll primers are intron-spanning.
Figure 1. Differential expression of 588 genes in autologous
PBMC and cultured CTCL cells analyzed by microarray
hybridization. mRNA has been isolated from CTCL cells and healthy
PBMC (both derived from patient SM) and reverse transcribed into
cDNA. Then, samples have been subjected for hybridization with an
array comprising 588 different genes related to human tumors. Results
are presented as an overlay of two blots. Black dots indicate mRNA that
is present in tumor cells only, the arrows indicate speci®c hybridization
of CTCL mRNA with a probe coding for IFN-g antagonist cytokine
(GenBank: A25270; cytokine IK). Insert: Expression of IK mRNA in
psoriasis vulgaris biopsies (MD, MB, BR), eczema biopsies (MT, HT),
atopic dermatitis biopsies (AE), cell cultures or tissue samples from
mycosis fungoides lesions (SW, DM, RM, TR, BB), PBMC from
patients with SeÂzary syndrome (CT, XB, SM, KH, ZA, WR), Jurkat
cells (Ju) and healthy donor PBMC (ZK). KH1 = as a control, RNA has
been isolated from sorted CD7+ PBMC only.
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¯uorescence-activated cell sorter (FACS) analysis and reverse
transcriptase±PCR in order to evaluate a functional signal
transduction pathway. There were prominent differences in basal
levels of protein expression and, however, after IFN stimulation no
consistent regulation of IFNR chains expression was detectable
(Table III). The same was true for healthy control PBMC and
Jurkat cells. Patient XB revealed strong expression of IFNGR1 and
2 chains, whereas patient PL expressed high amounts of IFNGR1,
which disappeared after stimulation and almost no expression of
IFNGR2. Reverse transcriptase±PCR analysis revealed the
presence of mRNA for all tested IFN signaling components in
both patients. The results for PBMC and Jurkat cells, however,
appeared heterogeneous.
IFN-g upregulated IK transcription in healthy donor PBMC
but not in CTCL patient derived CD4+ cells In order to
evaluate the functional properties of IK we incubated sorted patient
derived CD4+ cells (SM, CT, ZA, WR) and outgrown clonal
lymphoma cells (BB) with IFN-g and then isolated RNA for
reverse transcriptase±PCR analysis. With real-time PCR we have
been able to measure IK mRNA levels and b-actin mRNA levels as
external standards. Figure 3 shows the ratios of IK mRNA
compared with b-actin mRNA. Four of ®ve CTCL patients
showed almost no change in IK mRNA transcription after IFN-g
stimulation. One patient, however, responded with an increase of
IK mRNA. It is noteworthy that this particular patient showed an
extremely low level of IK mRNA in unstimulated CD4+ cells. In
comparison with that, we found an increase of IK mRNA levels
after IFN-g stimulation in CD4+ cells from healthy donors as well.
DISCUSSION
The study of differential gene expression patterns in tumor cells vs
their benign autologous counterpart by array technology opens
new dimensions in illuminating the molecular biology of
neoplasms. Expression levels of large amounts of genes can be
compared simultaneously and may help to identify characteristic
pro®les for tumor cells (Bittner et al, 2000). First approaches in
diffuse large B cell lymphomas demonstrate a correlation of tumor-
speci®c properties and prognosis (Alizadeh et al, 2000).
We cultured tumor cells from four patients with MF and
compared their gene expression pro®le with autologous or
allogenic CD4+ cells, respectively. In repeated experiments
CTCL biopsies and outgrown clonal T cells derived from 12 MF
and SS patients demonstrated consistent overexpression of factor IK
(Figs 1 and 3), an IFN-g inhibiting cytokine ®rst described by
Figure 2. Lack of HLA class II upregulation
in SS-derived cells upon IFN stimulation.
Freshly isolated PBMC from two SS patients
containing a clonal T cell population of 73.8%
(XB) and 81.3% (PL) of all CD4+ cells in the
blood were cultured 70 h with or without 500 U
per ml IFN-a, or IFN-g, respectively. Then, cells
were washed and stained with ¯uorescence
conjugated antibodies against HLA class II.
Stained cells were analyzed in a ¯ow cytometer
and gated on lymphocytes. Flow cytometric data
are presented as average shift (ratio of mean
¯uorescence of speci®c antibody vs appropriate
isotype-matched control antibody). Jurkat cells
showed no HLA class II expression at all (A).
Additionally, (B) compares histograms of isotype
controls (®lled gray curves) vs. speci®c antibody
stainings (open black curves).
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Krief et al (1994). This factor IK was shown to inhibit IFN-g-
induced expression of HLA class II antigen. Moreover, IK is
expressed in CD34+ hematopoietic progenitors, and its expression
can be upregulated during growth factor-induced differentiation
(Cao et al, 1997). Studies, that were done in IK transfected Raji B
cell lines led to a model in which IK inhibits the constitutive HLA
class II expression through repression of the class II transactivator
(CIITA) transcription. Differential expression of CIITA plays an
important part for the stabilization and activity of the transcription
complex. Several, yet unknown intermediate proteins may be
involved between IK and CIITA promotors (Vedrenne et al, 1997).
As CIITA is hardly expressed in IK transfected Raji B cells, it
appears that IK acts through a negative regulation of CIITA
expression. That means IK inhibits both, the CIITA promoter III
and IV of which the ®rst is responsible for a constitutive gene
expression and the latter renders responsible for an IFN-g induced
expression (Morris et al, 2000).
In order to investigate, whether the overexpressed IK is
functional we studied PBMC from advanced SS containing at
least 75% clonal T cells as assessed by FACS (Dummer et al, 1996,
2001). In contrast to normal PBMC, SS derived PBMC failed to
upregulate HLA class II expression upon IFN stimulation.
Stimulation with IFN-g does not in¯uence the IK levels in most
of the CTCL cells; however, normal PBMC respond with an
upregulation of IK mRNA transcription. This is especially
interesting as these cells are sensitive to IFN-g and increase the
HLA class II expression upon stimulation.
IFN-g binds to a speci®c ubiquitous cell surface receptor,
consisting of two transmembrane proteins, namely IFNGR1 chain,
IFNGR2 chain (Bach et al, 1996). The signal transduces through a
cascade of phosphorylations and then leads to the activation of
CIITA, which in turn induces HLA class II expression (Steimle et
al, 1994) and to some extend HLA class I expression as well (Martin
et al, 1997).
A natural role of IFN in tumor surveillance is demonstrated in
mouse tumor models where treatment with antibodies directed
against IFN leads to the stimulation of growth and proliferation of
tumor cells. The IFNGR±/± mouse model was used to address the
question whether IFN-g plays a crucial part in promoting host
surveillance that is capable of controlling the growth of primary
tumors. After treatment with chemical carcinogens, IFN-g-resistant
animals developed tumors more frequently than wild-type controls
(Kaplan et al, 1998).
Bach et al (1995) used an in vitro developmental system showing
that IFN-g stops the expression of the IFNGR2 chain, resulting in
Th1 cells that are unresponsive to IFN-g. This receptor chain loss
also occurred in IFN-g-treated Th2 cells (Bach et al, 1995). Their
data suggest that IFNGR2 loss is a speci®c response of CD4+ T
cells to IFN-g treatment rather than a Th1 speci®c differentiation
event. According to Bach et al (1995), it is also possible that
IFNGR2 overexpression is a sign of IFN-g depletion in SS blood.
We found similar heterogeneous results in our FACS analysis
(Table III). Although we showed the presence of most IFNR
chains in our patients, this does not prove a functional integrity of
Table III. Differential expression of IFNR chainsa
IFNAR1 IFNAR2 IFNGR1 IFNGR2





































































aFlow cytometric (FACS) data are presented as average shift (ratio of mean log ¯uorescence of speci®c antibody vs. appropriate isotype-matched control antibody).
Because of limited patient material only single experiments could be performed. RT±PCR analysis: + = strong band; 6 = faint band; ± = no band detectable; ND = not
determined. RT, reverse transcriptase.
Figure 3. IFN-g fails to enhance IK mRNA expression in CTCL
derived lymphocytes as measured by real-time reverse
transcriptase±PCR (LightCycler). From ®ve CTCL patients
malignant cells have been isolated and stimulated for 24 h with IFN-g
(500 U per ml). Then, RNA has been isolated and transcribed into
cDNA. The quality and quantity of cDNA has been checked with
primers speci®c for b-actin, followed by a PCR with primers speci®c for
IK. Data are expressed as ratios of IK transcripts vs b-actin transcripts.
Because of limited patient material only one experiment per sample
could be performed. In case of healthy control PBMC the mean of three
individual experiments including standard error of the mean (SEM) are
presented. Each single control sample showed higher IK level after IFN-
g stimulation.
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the IFN signaling pathway (Dummer et al, 2001). Further analysis
on mRNA levels revealed the presence of IFNR chain mRNA in
both investigated patients.
According to Vedrenne et al (1997) the overexpression of the IK
protein maintains CIITA expression under a threshold, inducing a
latent state of HLA-DR transcription repression. They suggest that
the IK/CIITA ratio represents a crucial controlling element for
HLA class II membrane expression. We believe that the threshold
for HLA class II expression can be easily overcome after IFN-g
stimulation in normal cells, by producing suf®cient amounts of
CIITA, which is then feedback regulated by rising IK levels. In
malignant cells, however, frequently de®cient in IFN-signaling this
regulatory loop is impaired, thus leading to constant high IK levels
and inhibition of IFN-g induced HLA class II protein expression.
Based on our data, we speculate that the clonal T cells create a
microenvironment where high levels of IK inhibit the bene®cial
effects of IFN-g in the surrounding tissue. A constant over-
expression of IK limits the CIITA activation and, therefore, the
induction of HLA class II protein. We are aware of the fact that this
regulatory pathway might be only one of many switches in a
complex microenvironmental network. The characterization of
factors involved in the control of HLA class II expression in healthy
and malignant cells, however, will be important to understand the
underlying molecular mechanisms. Successful immunointervention
in MF and SS might aim to restore reduced HLA class II facilitating
a better recognition by immunosurveillance (Martin et al, 1999).
We thank E. Niederer from the Institute of Biomedical Engineering at ETH Zurich
for providing us with sorted clonal cells and E. Laine at the Department of
Dermatology, Zurich for cDNA preparations and excellent technical support.
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